Winning for the third time in a row! Medicilon won the "Pharmaceutical Innovation Award - Top Ten Drug Innovation Service Institutions of the Year"

On April 30, the highly anticipated "The 4th Pharmaceutical Innovation Award" event came to a successful conclusion. At this event gathering industry elites, Medicilon USA Corp. (Medicilon) stood out with its cutting-edge innovative technology and excellent service capabilities, and won the "Pharmaceutical Innovation Award - Top Ten Drug Innovation Service Institutions of the Year".

Winning this honor for the third time undoubtedly represents a high recognition and affirmation of Medicilon's twenty years of empowerment in drug innovation!

The "Pharmaceutical Innovation Award" is organized by the Securities Times in 2020, aiming to promote the improvement of drug innovation capabilities by selecting outstanding drug innovation projects, outstanding companies and outstanding figures in China. The selection expert committee conducts selection based on the "Finance - Innovative Drug Index" database, drug evaluation and other related factors. The event attracted more than 100 pharmaceutical companies, innovative drug R&D companies, and medical service companies to participate. It has garnered widespread attention from industry experts and the academic community.

Deeply rooted in the genes of innovation, accumulating the driving force for development. Since its establishment twenty years ago, Medicilon has consistently adhered to driving comprehensive innovation through technological innovation, continuously investing in research and development resources, strengthening technological platform construction, and has grown into a leading one-stop preclinical research and development service platform in China. In 2023, Medicilon has been even more determined, adding several core technological platforms, such as the oligonucleotide drug development pilot platform, gene toxicity impurity assessment platform, and organoid platform based on iPS sources, further improving the one-stop innovative drug preclinical research and development service platform based on AI technology. At the same time, Medicilon has also strengthened the construction of the preclinical safety evaluation platform for traditional Chinese medicine, establishing platforms such as liver live puncture, muscle biopsy, and intrathecal injection platforms, providing solid support for early screening, druggability, and IND filing.

After twenty years of continuous hard work, Medicilon’s innovation tree has yielded fruitful results and is full of “fruits of empowerment”. Since 2015, Medicilon has been involved in the research and development of 421 new drugs and generic drug projects, which have been approved by the CFDA/NMPA, the US FDA, and the Australian TGA to enter clinical trials, accelerating the R&D process of new drug development for clients. As of the end of 2023, Medicilon has served 50+ ADC clients, among which 24 have been approved by the NMPA and FDA and entered the clinical trial stage. It has also served 40+ oligonucleotide clients and 3+ PROTAC-related clients, and has assisted in the approval of clinical trials for 8 GLP-1 related drugs.

In the future, Medicilon will always stand at the forefront of innovation and new drug development in the biopharmaceutical industry, actively building a more complete, efficient, and high-quality innovative technology service platform to contribute to the global development of drug innovation!

Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs

On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration. The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs. Gather and Work Together to Create Advantages Facilitate the Research and Development of Oncolytic Viruses, Nucleic Acids, Proteins and Other Drugs As a one-stop biopharmaceutical comprehensive preclinical R&D service CRO, Medicilon has been developing and accumulating for 20 years, always adhering to the spirit of innovation, and has successfully constructed bi/multi-specific antibodies, ADCs , mRNA vaccines , small nucleic acid drugs , PROTAC , and CGT technical service platform that have helped 421 INDs obtain clinical approval. It is this outstanding achievement that has earned Medicilon wide recognition in the industry and laid a solid foundation f...

阅读全文

The Launch Meeting was Held by Medicilon and DAC Biotech of the Contract Research on ADC Preclinical Study

Chuansha, Shanghai, Nov. 8th, 2019 — Medicilon held the launch meeting with Hangzhou DAC Biotech Co., Ltd to initiate the preclinical study of the antibody-drug-conjugate (ADC) DXC005, including the pharmacology study , DMPK study and the safety evaluation . Medicilon has previously completed integrated preclinical research on ADC drugs cooperating with DAC Biotech and other companies. Two of them has been approved by NMPA and entered Phase I clinical trials. About Hangzhou DAC Biotech Co., Ltd Hangzhou DAC Biotech, Co., Ltd was officially registered in HEDA Area, Hangzhou City, Zhejiang Province, China around the end of Year 2012, and is located nearby the bank of beautiful Qiantang River. The company focuses on developing conjugate of monoclonal antibody and small molecular cytotoxic drug, both of which are banded together with smart linkers. About Antibody-Drug-Conjugate (ADC) ADCs ...

阅读全文

A Nickel-Catalyzed Reductive Alkylation of Aryl Bromides and Chlorides for Sp3-Sp2 Bond Formation

In 2012, a nickel-catalyzed reductive alkylation method of aryl bromides and chlorides was reported. Under the optimized conditions, a variety of aryl and vinyl bromides as well as active aryl chloride can be reductively coupled with alkyl bromides in high yields. The protocols were highly functional-group tolerant and the reactions were not air or moisture sensitive. The reaction showed different chemoselectivity than conventional cross-coupling reactions. Substrates bearing both anelectrophilic and nucleophilic carbon resulted in selective coupling at the electrophilic carbon (R-X) and no reaction occurred at the nucleophilic carbon (R-[M]). The 2010 Nobel Prize in Chemistry was awarded for the Pd-catalyzed cross-coupling, and in the past decade the progress in cross-coupling has not only had a significant impact on academic research but has also influenced the industrial synthetic application. The transition-metal-catalyzed union of nucleophilic organo-boronic acids with elect...

阅读全文

Shanghai Medicilon Inc.

搜索此博客